[en] Multiple myeloma is the second most frequent hematological malignancy. Unfortunately, it is still incurable. A better understanding of the myeloma pathophysiology favored the development of new therapeutic molecules that improved both survival and quality of life of patients. Diagnostic and prognostic criteria for myeloma have been reviewed and help to detect multiple myeloma more early and further help to define the best therapeutic strategy. These new regimens are associated with side effects that differ from those of classic molecules and that we have to be able to recognize and to treat appropriately.
Kazandjian D. Multiple myeloma epidemiology and survival, a unique malignancy. Semin Oncol 2016; 43:676‑81.
Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet 2000;355:248‑50.
Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;12:538‑48.
Caers J, Fernández de Larrea C, Leleu X, et al. The changing landscape of smoldering multiple myeloma: an European perspective. Oncologist 2016;21:333‑42.
Dispenzieri A, Rajkumar V, Gertz MA, et al. Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and risk‑adapted therapy (mSMART): consensus statement. Mayo Clin Proc 2007;82:323‑41.
Palumbo A, Avet‑Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol 2015;33:2863‑9.
Lichtenstein A, Tu Y, Fady C, et al. Interleukin‑6 inhibits apoptosis of malignant plasma cells. Cell Immunol 1995;162:248‑55.
van de Donk NWCJ, Richardson PG, Malavasi F. CD38 antibodies in multiplemyeloma: back to the future. Blood. 2018;131:13‑29.
Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 2008;14:2775‑84.
Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 2015;73:621‑31
Ludwig H, Delforge M, Facon T, et al. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia 2017 (epub ahead of print).
